A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity

Autores
Bellier, Bertrand; Saura, Alicia; Luján, Lucas Agustín; Molina, Cecilia Rita; Lujan, Hugo Daniel; Klatzmann, David
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.
Fil: Bellier, Bertrand. Université Pierre et Marie Curie; Francia
Fil: Saura, Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Luján, Lucas Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Molina, Cecilia Rita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Lujan, Hugo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Klatzmann, David. Hôpital Universitaire Pitié Salpêtrière; Francia. Université Pierre et Marie Curie; Francia
Materia
COVID-19
MUCOSAL IMMUNITY
ORAL VACCINATION
VACCINE
VLP (VIRUS-LIKE PARTICLE)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/201000
Acceder
id CONICETDig_7d834d54b19801337f604bdbb87194c6
oai_identifier_str oai:ri.conicet.gov.ar:11336/201000
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective ImmunityBellier, BertrandSaura, AliciaLuján, Lucas AgustínMolina, Cecilia RitaLujan, Hugo DanielKlatzmann, DavidCOVID-19MUCOSAL IMMUNITYORAL VACCINATIONVACCINEVLP (VIRUS-LIKE PARTICLE)https://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.Fil: Bellier, Bertrand. Université Pierre et Marie Curie; FranciaFil: Saura, Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; ArgentinaFil: Luján, Lucas Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; ArgentinaFil: Molina, Cecilia Rita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; ArgentinaFil: Lujan, Hugo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; ArgentinaFil: Klatzmann, David. Hôpital Universitaire Pitié Salpêtrière; Francia. Université Pierre et Marie Curie; FranciaFrontiers Media2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/201000Bellier, Bertrand; Saura, Alicia; Luján, Lucas Agustín; Molina, Cecilia Rita; Lujan, Hugo Daniel; et al.; A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity; Frontiers Media; Frontiers in Immunology; 13; 2-2022; 1-101664-3224CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2022.837443/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2022.837443info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:27:02Zoai:ri.conicet.gov.ar:11336/201000instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:27:03.133CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
title A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
spellingShingle A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
Bellier, Bertrand
COVID-19
MUCOSAL IMMUNITY
ORAL VACCINATION
VACCINE
VLP (VIRUS-LIKE PARTICLE)
title_short A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
title_full A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
title_fullStr A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
title_full_unstemmed A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
title_sort A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity
dc.creator.none.fl_str_mv Bellier, Bertrand
Saura, Alicia
Luján, Lucas Agustín
Molina, Cecilia Rita
Lujan, Hugo Daniel
Klatzmann, David
author Bellier, Bertrand
author_facet Bellier, Bertrand
Saura, Alicia
Luján, Lucas Agustín
Molina, Cecilia Rita
Lujan, Hugo Daniel
Klatzmann, David
author_role author
author2 Saura, Alicia
Luján, Lucas Agustín
Molina, Cecilia Rita
Lujan, Hugo Daniel
Klatzmann, David
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
MUCOSAL IMMUNITY
ORAL VACCINATION
VACCINE
VLP (VIRUS-LIKE PARTICLE)
topic COVID-19
MUCOSAL IMMUNITY
ORAL VACCINATION
VACCINE
VLP (VIRUS-LIKE PARTICLE)
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.
Fil: Bellier, Bertrand. Université Pierre et Marie Curie; Francia
Fil: Saura, Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Luján, Lucas Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Molina, Cecilia Rita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Lujan, Hugo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas. Universidad Católica de Córdoba. Centro de Investigación y Desarrollo en Inmunología y Enfermedades Infecciosas; Argentina
Fil: Klatzmann, David. Hôpital Universitaire Pitié Salpêtrière; Francia. Université Pierre et Marie Curie; Francia
description An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.
publishDate 2022
dc.date.none.fl_str_mv 2022-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/201000
Bellier, Bertrand; Saura, Alicia; Luján, Lucas Agustín; Molina, Cecilia Rita; Lujan, Hugo Daniel; et al.; A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity; Frontiers Media; Frontiers in Immunology; 13; 2-2022; 1-10
1664-3224
CONICET Digital
CONICET
url http://hdl.handle.net/11336/201000
identifier_str_mv Bellier, Bertrand; Saura, Alicia; Luján, Lucas Agustín; Molina, Cecilia Rita; Lujan, Hugo Daniel; et al.; A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity; Frontiers Media; Frontiers in Immunology; 13; 2-2022; 1-10
1664-3224
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2022.837443/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2022.837443
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781835190730752
score 12.982451

Publicaciones similares